[ Edico Genome raises $22M in Series B funding ]
Edico Genome has raised $22 million in Series B funding.
Founded in 2013, Edico Genome develops an automated solution that analyses sequencing data for critically ill newborns, cancer patients, scientists and drug developers.
The new financing will be used to fuel expansion and further development of Edico’s Dragen technology. There’s a lot of additional engineering and software development that needs to be done, and Edico also plans to expand its sales and marketing team.
|City||La Jolla, California|
|Founder / CEO||Pieter van Rooyen|
|Dell Technologies Capital|
|Previous Investors||Qualcomm Ventures|